FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wylie Vale

Research Profile

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Joan M Vaughan; Cynthia J Donaldson; Wolfgang H Fischer; Marilyn H Perrin; Jean E Rivier; Paul E Sawchenko; Wylie W Vale
Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.
Adi Neufeld-Cohen; Henry J Olverman; Evan D Paul; Jonathan R Seckl; Elizabeth Skinner; Wylie W Vale; Joan M Vaughan; Roderick N Carter; Alon Chen; Orna Issler; Paul A T Kelly; Yael Kuperman; Christopher A Lowry; Pauline M Jamieson
Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge.
Louise M Bilezikjian; Alissa N Blackler; Nicholas J Justice; Ezra Wiater; Wylie W Vale
Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wylie Vale (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Joan M Vaughan; Cynthia J Donaldson; Wolfgang H Fischer; Marilyn H Perrin; Jean E Rivier; Paul E Sawchenko; Wylie W Vale
Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.
Endocrinology 2013;154(4):1553-64.
2012: Adi Neufeld-Cohen; Henry J Olverman; Evan D Paul; Jonathan R Seckl; Elizabeth Skinner; Wylie W Vale; Joan M Vaughan; Roderick N Carter; Alon Chen; Orna Issler; Paul A T Kelly; Yael Kuperman; Christopher A Lowry; Pauline M Jamieson
Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge.
Biological psychiatry 2012;72(6):437-47.
2012: Louise M Bilezikjian; Alissa N Blackler; Nicholas J Justice; Ezra Wiater; Wylie W Vale
Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.
Molecular and cellular endocrinology 2012;359(1-2):43-52.
2012: Talitha van der Meulen; Ruiyu Xie; Olivia G Kelly; Maike Sander; Wylie W Vale; Mark Huising
Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells.
PloS one 2012;7(12):e52181.
2011: Pauline M Jamieson; P A T Kelly; Y Kuperman; Nicholas M Morton; K J Mustard; Jonathan R Seckl; David G Brownstein; R N Carter; Alon Chen; M E Cleasby; C N Hahn; D Grahame Hardie; J M Vaughan; Wylie W Vale
Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet.
Diabetologia 2011;54(9):2392-403.
2011: Irene Coin; Marilyn H Perrin; Wylie W Vale; Lei Wang
Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison.
Angewandte Chemie (International ed. in English) 2011;50(35):8077-81.
2011: Gemma Fraga Veloso; Dan G Ohad; Andrew J Francis; Joan M Vaughan; David G Brownstein; Geoffrey J Culshaw; Wylie W Vale; Anne T French; Pauline M Jamieson
Expression of urocortin peptides in canine myocardium and plasma.
Veterinary journal (London, England : 1997) 2011;188(3):318-24.
2011: Mark Huising; A P Pilbrow; Masahito Max Matsumoto; T van der Meulen; H Park; Joan M Vaughan; Soon Lee; Wylie W Vale
Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets.
Endocrinology 2011;152(1):138-50.
2010: Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Jean E Rivier; Wylie W Vale; Roland Riek
NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.
The Journal of biological chemistry 2010;285(49):38580-9.
2010: Adi Neufeld-Cohen; Michael M Tsoory; Andrew K Evans; Dmitriy Getselter; Shosh Gil; Christopher A Lowry; Wylie W Vale; Alon Chen
A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(44):19020-5.
2010: Silvia Meili-Butz; Katrin Bühler; Dietlinde John; Peter Buser; Wylie W Vale; Kirk L Peterson; Marijke Brink; Thomas Dieterle
Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure.
European journal of heart failure 2010;12(8):797-804.
2010: Mark Huising; Talitha van der Meulen; Joan M Vaughan; Masahito Max Matsumoto; Cynthia J Donaldson; Hannah Park; Nils Billestrup; Wylie W Vale
CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(2):912-7.
2009: Eva Fekete; Yu Zhao; C Li; Valentina Sabino; Wylie W Vale; Eric P Zorrilla
Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNA.
Neuroscience 2009;162(1):5-13.
2009: J A Kelber; A D Panopoulos; G Shani; E C Booker; Juan Carlos Izpisúa Belmonte; Wylie W Vale; Peter Gray
Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Oncogene 2009;28(24):2324-36.
2009: Thomas Dieterle; Silvia Meili-Butz; Katrin Bühler; Christian Morandi; Dietlinde John; Peter T Buser; Jean Rivier; Wylie W Vale; Kirk L Peterson; Marijke Brink
Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy?
Hypertension 2009;53(4):739-44.
2009: Amy L Blount; Karsten Schmidt; Nicholas J Justice; Wylie W Vale; Wolfgang H Fischer; Louise M Bilezikjian
FoxL2 and Smad3 coordinately regulate follistatin gene transcription.
The Journal of biological chemistry 2009;284(12):7631-45.
2008: Mark Huising; Joan M Vaughan; Shaili H Shah; Katherine L Grillot; Cynthia J Donaldson; Jean Rivier; Gert Flik; Wylie W Vale
Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.
The Journal of biological chemistry 2008;283(14):8902-12.
2008: Amy L Blount; Joan M Vaughan; Wylie W Vale; Louise M Bilezikjian
A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene.
The Journal of biological chemistry 2008;283(11):7016-26.
2008: Zhengrong Hao; Yan Huang; Jake Cleman; Ion S Jovin; Wylie W Vale; Tracy L Bale; Frank J Giordano
Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(10):3939-44.
2008: Jonathan A Kelber; Gidi Shani; Evan C Booker; Wylie W Vale; Peter Gray
Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
The Journal of biological chemistry 2008;283(8):4490-500.
2007: Marilyn H Perrin; Christy Rani R Grace; Michael R DiGruccio; Wolfgang H Fischer; Samir K Maji; Jeffrey P Cantle; Sean Smith; Gerard Manning; Wylie W Vale; Roland Riek
Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors.
The Journal of biological chemistry 2007;282(52):37529-36.
2007: Christy Rani R Grace; Marilyn H Perrin; Jeffrey P Cantle; Wylie W Vale; Jean E Rivier; Roland Riek
Common and divergent structural features of a series of corticotropin releasing factor-related peptides.
Journal of the American Chemical Society 2007;129(51):16102-14.
2007: Yu Zhao; Glenn R Valdez; Eva Fekete; Jean E Rivier; Wylie W Vale; Kenner C Rice; Friedbert Weiss; Eric P Zorrilla
Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.
The Journal of pharmacology and experimental therapeutics 2007;323(3):846-54.
2007: Antoine Tabarin; Yolanda Diz-Chaves; D Consoli; M Monsaingeon; Tracy L Bale; M D Culler; R Datta; F Drago; Wylie W Vale; George F Koob; Eric P Zorrilla; Angelo Contarino
Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis.
The European journal of neuroscience 2007;26(8):2303-14.
2007: Eva Fekete; Koki Inoue; Yu Zhao; Jean E Rivier; Wylie W Vale; Attila Szücs; George F Koob; Eric P Zorrilla
Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(5):1052-68.
2007: Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Michael R DiGruccio; Jeffrey P Cantle; Jean E Rivier; Wylie W Vale; Roland Riek
Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(12):4858-63.
2006: Sebastian Pollandt; Jie Liu; LUIS OROZCO-CABAL; Dimitri E Grigoriadis; Wylie W Vale; Joel P Gallagher; Patricia Shinnick-Gallagher
Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA.
The European journal of neuroscience 2006;24(6):1733-43.
2006: Louise M Bilezikjian; Amy L Blount; Cynthia J Donaldson; Wylie W Vale
Pituitary actions of ligands of the TGF-beta family: activins and inhibins.
Reproduction (Cambridge, England) 2006;132(2):207-15.
2006: Marilyn H Perrin; Christy Rani R Grace; Roland Riek; Wylie W Vale
The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.
Annals of the New York Academy of Sciences 2006;1070():105-19.
2006: Ezra Wiater; Craig A Harrison; Kathy A Lewis; Peter Gray; Wylie W Vale
Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.
The Journal of biological chemistry 2006;281(25):17011-22.
2006: George P Allendorph; Wylie W Vale; Senyon Choe
Structure of the ternary signaling complex of a TGF-beta superfamily member.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(20):7643-8.
2006: Sean M Smith; Joan M Vaughan; Cynthia J Donaldson; Rosette E Fernandez; Chien Li; Alon Chen; Wylie W Vale
Cocaine- and amphetamine-regulated transcript is localized in pituitary lactotropes and is regulated during lactation.
Endocrinology 2006;147(3):1213-23.
2006: Kendall M Carlin; Wylie W Vale; Tracy L Bale
Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(9):3462-7.
2006: Sean M Smith; Wylie W Vale
The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress.
Dialogues in clinical neuroscience 2006;8(4):383-95.
2005: Craig A Harrison; Peter Gray; Wylie W Vale; David M Robertson
Antagonists of activin signaling: mechanisms and potential biological applications.
Trends in endocrinology and metabolism: TEM 2005;16(2):73-8.
2005: Alon M Chen; Marilyn H Perrin; Michael R DiGruccio; Joan M Vaughan; Bhawanjit K Brar; Carlos M Arias; Kathy A Lewis; Jean E Rivier; Paul E Sawchenko; Wylie W Vale
A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(7):2620-5.
2005: Jie Liu; Baojian Yu; LUIS OROZCO-CABAL; Dimitri E Grigoriadis; Jean Rivier; Wylie W Vale; Patricia Shinnick-Gallagher; Joel P Gallagher
Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(3):577-83.
2005: Charles Nemeroff; Wylie W Vale
The neurobiology of depression: inroads to treatment and new drug discovery.
The Journal of clinical psychiatry 2005;66 Suppl 7():5-13.
2004: Mariarosa G Spina; Kristina Langnaese; Gabriella F Orlando; Thomas F W Horn; Jean Rivier; Wylie W Vale; Gerald Wolf; Mario Engelmann
Colocalization of urocortin and neuronal nitric oxide synthase in the hypothalamus and Edinger-Westphal nucleus of the rat.
The Journal of comparative neurology 2004;479(3):271-86.
2004: Sean M Smith; Joan M Vaughan; Cynthia J Donaldson; Jean Rivier; Chien Li; Alon Chen; Wylie W Vale
Cocaine- and amphetamine-regulated transcript activates the hypothalamic-pituitary-adrenal axis through a corticotropin-releasing factor receptor-dependent mechanism.
Endocrinology 2004;145(11):5202-9.
2004: Louise M Bilezikjian; Amy L Blount; Angela M O Leal; Cynthia J Donaldson; Wolfgang H Fischer; Wylie W Vale
Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin.
Molecular and cellular endocrinology 2004;225(1-2):29-36.
2004: Eric P Zorrilla; Lindsay E Reinhardt; Glenn R Valdez; Koki Inoue; Jean E Rivier; Wylie W Vale; George F Koob
Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
The Journal of pharmacology and experimental therapeutics 2004;310(3):1027-34.
2004: Christy Rani R Grace; Marilyn H Perrin; Michael R DiGruccio; Charleen L Miller; Jean E Rivier; Wylie W Vale; Roland Riek
NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(35):12836-41.
2004: Victoria B Risbrough; Richard L Hauger; Amanda L Roberts; Wylie W Vale; Mark A Geyer
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004;24(29):6545-52.
2004: Jie Liu; Baojian Yu; Volker Neugebauer; Dimitri E Grigoriadis; Jean Rivier; Wylie W Vale; Patricia Shinnick-Gallagher; Joel P Gallagher
Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004;24(16):4020-9.
2004: Sam R J Hoare; Susan K Sullivan; David A Schwarz; Nicholas Ling; Wylie W Vale; Paul Crowe; Dimitri E Grigoriadis
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Biochemistry 2004;43(13):3996-4011.
2004: Tracy L Bale; Masahiko Hoshijima; Yusu Gu; Nancy Dalton; Keith R Anderson; Kuo-Fen Lee; Jean Rivier; Kenneth R Chien; Wylie W Vale; Kirk L Peterson
The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(10):3697-702.
2004: Luise Pernar; Andre L Curtis; Wylie W Vale; Jean E Rivier; Rita J Valentino
Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004;24(6):1305-11.
2004: Tracy L Bale; Wylie W Vale
CRF and CRF receptors: role in stress responsivity and other behaviors.
Annual review of pharmacology and toxicology 2004;44():525-57.
2003: Glenn R Valdez; Eric P Zorrilla; Jean Rivier; Wylie W Vale; George F Koob
Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist.
Brain research 2003;980(2):206-12.
2003: Alon Chen; Joan Vaughan; Wylie W Vale
Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways.
Molecular endocrinology (Baltimore, Md.) 2003;17(8):1622-39.
2003: P Sinnayah; John Blair-West; Mary McBurnie; Michael J McKinley; Brian J Oldfield; J Rivier; Wylie W Vale; Lesley L Walker; Richard S Weisinger; Derek A Denton
The effect of urocortin on ingestive behaviours and brain Fos immunoreactivity in mice.
The European journal of neuroscience 2003;18(2):373-82.
2003: Tracy L Bale; Wylie W Vale
Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(12):5295-301.
2003: Tracy L Bale; Keith R Anderson; Amanda J Roberts; Kuo-Fen Lee; Tim Nagy; Wylie W Vale
Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold.
Endocrinology 2003;144(6):2580-7.
2003: Marilyn H Perrin; Michael R DiGruccio; Steven C Koerber; Jean E Rivier; Koichi S Kunitake; Deborah L Bain; Wolfgang H Fischer; Wylie W Vale
A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity.
The Journal of biological chemistry 2003;278(18):15595-600.
2003: Angela M O Leal; Amy L Blount; Cynthia J Donaldson; Louise M Bilezikjian; Wylie W Vale
Regulation of follicle-stimulating hormone secretion by the interactions of activin-A, dexamethasone and testosterone in anterior pituitary cell cultures of male rats.
Neuroendocrinology 2003;77(5):298-304.
2003: Koki Inoue; Glenn R Valdez; Teresa Reyes; Lindsay E Reinhardt; Antoine Tabarin; Jean Rivier; Wylie W Vale; Paul E Sawchenko; George F Koob; Eric P Zorrilla
Human urocortin II, a selective agonist for the type 2 corticotropin-releasing factor receptor, decreases feeding and drinking in the rat.
The Journal of pharmacology and experimental therapeutics 2003;305(1):385-93.
2003: Kazunori Kageyama; Chien Li; Wylie W Vale
Corticotropin-releasing factor receptor type 2 messenger ribonucleic acid in rat pituitary: localization and regulation by immune challenge, restraint stress, and glucocorticoids.
Endocrinology 2003;144(4):1524-32.
2003: Richard L Hauger; Dimitri E Grigoriadis; Mary Dallman; Paul M Plotsky; Wylie W Vale; Frank M Dautzenberg
International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands.
Pharmacological reviews 2003;55(1):21-6.
2003: Tracy L Bale; Frank J Giordano; Wylie W Vale
A new role for corticotropin-releasing factor receptor-2: suppression of vascularization.
Trends in cardiovascular medicine 2003;13(2):68-71.
2003: Louise M Bilezikjian; Angela M O Leal; Amy L Blount; Anne Z Corrigan; Andrew Turnbull; Wylie W Vale
Rat anterior pituitary folliculostellate cells are targets of interleukin-1beta and a major source of intrapituitary follistatin.
Endocrinology 2003;144(2):732-40.
2003: Jay Groppe; Jason Greenwald; Ezra Wiater; Joaquin Rodriguez-Leon; Aris N Economides; Witek Kwiatkowski; Kandan Baban; Markus Affolter; Wylie W Vale; Juan Carlos Izpisua Belmonte; Senyon Choe
Structural basis of BMP signaling inhibition by Noggin, a novel twelve-membered cystine knot protein.
The Journal of bone and joint surgery. American volume 2003;85-A Suppl 3():52-8.
2003: Kazunori Kageyama; Georges Gaudriault; Toshihiro Suda; Wylie W Vale
Regulation of corticotropin-releasing factor receptor type 2beta mRNA via cyclic AMP pathway in A7r5 aortic smooth muscle cells.
Cellular signalling 2003;15(1):17-25.
2002: Jay Groppe; Jason Greenwald; Ezra Wiater; Joaquin Rodriguez-Leon; Aris N Economides; Witek Kwiatkowski; Markus Affolter; Wylie W Vale; Juan Carlos Izpisúa Belmonte; Senyon Choe
Structural basis of BMP signalling inhibition by the cystine knot protein Noggin.
Nature 2002;420(6916):636-42.
2002: Miriam T Rademaker; Christopher J Charles; Eric A Espiner; Steve Fisher; Christopher M Frampton; Carl M J Kirkpatrick; John G Lainchbury; M Gary Nicholls; A Mark Richards; Wylie W Vale
Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep.
Journal of the American College of Cardiology 2002;40(8):1495-505.
2002: Tracy L Bale; Kuo-Fen Lee; Wylie W Vale
The role of corticotropin-releasing factor receptors in stress and anxiety.
Integrative and comparative biology 2002;42(3):552-5.
2002: Tracy L Bale; Frank J Giordano; Reed P Hickey; Yan Huang; Anjali K Nath; Kirk L Peterson; Wylie W Vale; Kuo-Fen Lee
Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(11):7734-9.
2002: Leigh A MacConell; Angela M O Leal; Wylie W Vale
The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions.
Endocrinology 2002;143(3):1066-75.
2002: Chien Li; Joan Vaughan; Paul E Sawchenko; Wylie W Vale
Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(3):991-1001.
2002: Tracy L Bale; Roberto Picetti; Angelo Contarino; George F Koob; Wylie W Vale; Kuo-Fen Lee
Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(1):193-9.
2001: Marilyn H Perrin; Wolfgang H Fischer; Koichi S Kunitake; A Grey Craig; Steven C Koerber; Laura Cervini; Jean E Rivier; Jay Groppe; Jason Greenwald; S Møller Nielsen; Wylie W Vale
Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor.
The Journal of biological chemistry 2001;276(34):31528-34.
2001: Kathy Lewis; Chien Li; Marilyn H Perrin; Amy L Blount; Koichi S Kunitake; Cynthia J Donaldson; Joan Vaughan; Teresa Reyes; Jozsef Gulyas; W Fischer; Louise M Bilezikjian; Jean Rivier; Paul E Sawchenko; Wylie W Vale
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(13):7570-5.
2001: Louise M Bilezikjian; Amy L Blount; Anne Z Corrigan; A Leal; Yan Chen; Wylie W Vale
Actions of activins, inhibins and follistatins: implications in anterior pituitary function.
Clinical and experimental pharmacology & physiology 2001;28(3):244-8.
2001: Louise M Bilezikjian; Anne Z Corrigan; Amy L Blount; Yan Chen; Wylie W Vale
Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
Endocrinology 2001;142(3):1065-72.
2001: Teresa Reyes; Kathy Lewis; Marilyn H Perrin; Koichi S Kunitake; Joan Vaughan; C A Arias; John B Hogenesch; Jozsef Gulyas; Jean Rivier; Wylie W Vale; Paul E Sawchenko
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(5):2843-8.
2000: Susan M Nielsen; L Z Nielsen; Siv A Hjorth; Marilyn H Perrin; Wylie W Vale
Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(18):10277-81.
2000: MJ Bradbury; Mary McBurnie; Derek A Denton; Kuo-Fen Lee; Wylie W Vale
Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice.
Endocrinology 2000;141(8):2715-24.
2000: Angelo Contarino; F Dellu; George F Koob; George W Smith; Kuo-Fen Lee; Wylie W Vale; Lisa H Gold
Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice.
Endocrinology 2000;141(7):2698-702.
2000: Kazunori Kageyama; Georges Gaudriault; MJ Bradbury; Wylie W Vale
Regulation of corticotropin-releasing factor receptor type 2 beta messenger ribonucleic acid in the rat cardiovascular system by urocortin, glucocorticoids, and cytokines.
Endocrinology 2000;141(7):2285-93.
2000: Tracy L Bale; Angelo Contarino; George W Smith; R Chan; Lisa H Gold; Paul E Sawchenko; George F Koob; Wylie W Vale; Kuo-Fen Lee
Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.
Nature genetics 2000;24(4):410-4.
2000: RK Chan; Wylie W Vale; Paul E Sawchenko
Paradoxical activational effects of a corticotropin-releasing factor-binding protein "ligand inhibitor" in rat brain.
Neuroscience 2000;101(1):115-29.
1999: Jackson C Bittencourt; Joan Vaughan; C Arias; Robert A Rissman; Wylie W Vale; Paul E Sawchenko
Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors.
The Journal of comparative neurology 1999;415(3):285-312.
1999: Kazunori Kageyama; MJ Bradbury; L Zhao; Amy L Blount; Wylie W Vale
Urocortin messenger ribonucleic acid: tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids.
Endocrinology 1999;140(12):5651-8.
1999: Marilyn H Perrin; Wylie W Vale
Corticotropin releasing factor receptors and their ligand family.
Annals of the New York Academy of Sciences 1999;885():312-28.
1999: Charles Peto; C Arias; Wylie W Vale; Paul E Sawchenko
Ultrastructural localization of the corticotropin-releasing factor-binding protein in rat brain and pituitary.
The Journal of comparative neurology 1999;413(2):241-54.
1999: Jean E Rivier; Dean A Kirby; SL Lahrichi; Anne Z Corrigan; Wylie W Vale; Catherine Rivier
Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
Journal of medicinal chemistry 1999;42(16):3175-82.
1999: Kazuaki Takabe; JJ Lebrun; Y Nagashima; Y Ichikawa; M Mitsuhashi; Nobuyoshi Momiyama; T Ishikawa; H Shimada; Wylie W Vale
Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation.
Endocrinology 1999;140(7):3125-32.
1999: JM Aubry; Giacomo Pozzoli; Wylie W Vale
Chronic treatment with the antidepressant amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala.
Neuroscience letters 1999;266(3):197-200.
1999: Cynthia J Donaldson; Joan M Vaughan; Anne Z Corrigan; Wolfgang H Fischer; Wylie W Vale
Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
Endocrinology 1999;140(4):1760-6.
1999: Andrew Turnbull; George W Smith; Soon Lee; Wylie W Vale; Kuo-Fen Lee; Catherine Rivier
CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation.
Endocrinology 1999;140(2):1013-7.
1999: Marilyn H Perrin; S W Sutton; Laura Cervini; Jean E Rivier; Wylie W Vale
Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
The Journal of pharmacology and experimental therapeutics 1999;288(2):729-34.
1999: Andrew Turnbull; Joan Vaughan; Jean E Rivier; Wylie W Vale; Catherine Rivier
Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat.
Endocrinology 1999;140(1):71-8.
1999: Jason Greenwald; Wolfgang H Fischer; Wylie W Vale; Senyon Choe
Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.
Nature structural biology 1999;6(1):18-22.
1998: Louise M Bilezikjian; Andrew Turnbull; Anne Z Corrigan; Amy L Blount; Catherine Rivier; Wylie W Vale
Interleukin-1beta regulates pituitary follistatin and inhibin/activin betaB mRNA levels and attenuates FSH secretion in response to activin-A.
Endocrinology 1998;139(7):3361-4.
1998: L Zhao; C J Donaldson; G W Smith; Wylie W Vale
The structures of the mouse and human urocortin genes (Ucn and UCN).
Genomics 1998;50(1):23-33.
1998: Laura Cervini; Cynthia J Donaldson; Steven C Koerber; Wylie W Vale; Jean E Rivier
Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Journal of medicinal chemistry 1998;41(5):717-27.
1998: Marilyn H Perrin; S Sutton; D L Bain; W T Berggren; Wylie W Vale
The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin.
Endocrinology 1998;139(2):566-70.
1997: JJ Lebrun; Wylie W Vale
Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
Molecular and cellular biology 1997;17(3):1682-91.
1996: Louise M Bilezikjian; Anne Z Corrigan; A L Blount; Wylie W Vale
Pituitary follistatin and inhibin subunit messenger ribonucleic acid levels are differentially regulated by local and hormonal factors.
Endocrinology 1996;137(10):4277-84.
1996: D P Behan; D Cepoi; Wolfgang H Fischer; M Park; S Sutton; Philip J Lowry; Wylie W Vale
Characterization of a sheep brain corticotropin releasing factor binding protein (Brain Research 709 (1996) 265-274) (BRES 11959).
Brain research 1996;732(1-2):267.
1996: Stephen C Heinrichs; Mary P Stenzel-Poore; Lisa H Gold; E Battenberg; F E Bloom; George F Koob; Wylie W Vale; E M Pich
Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor.
Neuroscience 1996;74(2):303-11.
1996: Cynthia J Donaldson; S W Sutton; Marilyn H Perrin; Anne Z Corrigan; K A Lewis; Jean E Rivier; J M Vaughan; Wylie W Vale
Cloning and characterization of human urocortin.
Endocrinology 1996;137(9):3896.
1996: Cynthia J Donaldson; S W Sutton; Marilyn H Perrin; Anne Z Corrigan; K A Lewis; Jean E Rivier; J M Vaughan; Wylie W Vale
Cloning and characterization of human urocortin.
Endocrinology 1996;137(5):2167-70.
1996: D P Behan; Errol B De Souza; E Potter; Paul E Sawchenko; Philip J Lowry; Wylie W Vale
Modulatory actions of corticotropin-releasing factor-binding protein.
Annals of the New York Academy of Sciences 1996;780():81-95.
1996: D P Behan; D Cepoi; Wolfgang H Fischer; M Park; S Sutton; Philip J Lowry; Wylie W Vale
Characterization of a sheep brain corticotropin releasing factor binding protein.
Brain research 1996;709(2):265-74.
1996: Giacomo Pozzoli; Louise M Bilezikjian; Marilyn H Perrin; A L Blount; Wylie W Vale
Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures.
Endocrinology 1996;137(1):65-71.
1995: K Tsuchida; J M Vaughan; E Wiater; D Gaddy-Kurten; Wylie W Vale
Inactivation of activin-dependent transcription by kinase-deficient activin receptors.
Endocrinology 1995;136(12):5493-503.
1995: D Gaddy-Kurten; Wylie W Vale
Activin increases phosphorylation and decreases stability of the transcription factor Pit-1 in MtTW15 somatotrope cells.
The Journal of biological chemistry 1995;270(48):28733-9.
1995: Claudio D Stern; R T Yu; A Kakizuka; C R Kintner; L S Mathews; Wylie W Vale; Ronald M Evans; K Umesono
Activin and its receptors during gastrulation and the later phases of mesoderm development in the chick embryo.
Developmental biology 1995;172(1):192-205.
1995: D P Behan; Errol B De Souza; Philip J Lowry; E Potter; Paul E Sawchenko; Wylie W Vale
Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
Frontiers in neuroendocrinology 1995;16(4):362-82.
1995: S W Sutton; D P Behan; SL Lahrichi; R Kaiser; Anne Z Corrigan; P Lowry; E Potter; Marilyn H Perrin; Jean Rivier; Wylie W Vale
Ligand requirements of the human corticotropin-releasing factor-binding protein.
Endocrinology 1995;136(3):1097-102.
1994: Peter Stenzel; Lynne M Angerer; B J Smith; Robert Clifford Angerer; Wylie W Vale
The univin gene encodes a member of the transforming growth factor-beta superfamily with restricted expression in the sea urchin embryo.
Developmental biology 1994;166(1):149-58.
1994: P Hüsken-Hindi; K Tsuchida; M Park; Anne Z Corrigan; J M Vaughan; Wylie W Vale; Wolfgang H Fischer
Monomeric activin A retains high receptor binding affinity but exhibits low biological activity.
The Journal of biological chemistry 1994;269(30):19380-4.
1994: Mary P Stenzel-Poore; Stephen C Heinrichs; S Rivest; George F Koob; Wylie W Vale
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(5 Pt 1):2579-84.
1994: V A Cameron; E Nishimura; L S Mathews; K A Lewis; Paul E Sawchenko; Wylie W Vale
Hybridization histochemical localization of activin receptor subtypes in rat brain, pituitary, ovary, and testis.
Endocrinology 1994;134(2):799-808.
1993: K Tsuchida; L S Mathews; Wylie W Vale
Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(23):11242-6.
1993: Marilyn H Perrin; Cynthia J Donaldson; R Chen; K A Lewis; Wylie W Vale
Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor.
Endocrinology 1993;133(6):3058-61.
1993: Louise M Bilezikjian; J M Vaughan; Wylie W Vale
Characterization and the regulation of inhibin/activin subunit proteins of cultured rat anterior pituitary cells.
Endocrinology 1993;133(6):2545-53.
1993: D P Behan; E Potter; S Sutton; W Fischer; Philip J Lowry; Wylie W Vale
Corticotropin-releasing factor-binding protein. A putative peripheral and central modulator of the CRF family of neuropeptides.
Annals of the New York Academy of Sciences 1993;697():1-8.
1993: R Chen; K A Lewis; Marilyn H Perrin; Wylie W Vale
Expression cloning of a human corticotropin-releasing-factor receptor.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(19):8967-71.
1993: L S Mathews; Wylie W Vale
Characterization of type II activin receptors. Binding, processing, and phosphorylation.
The Journal of biological chemistry 1993;268(25):19013-8.
1993: D G Parkes; Wylie W Vale
Contrasting actions of melanin-concentrating hormone and neuropeptide-E-I on posterior pituitary function.
Annals of the New York Academy of Sciences 1993;680():588-90.
1993: J M Vaughan; Wylie W Vale
Alpha 2-macroglobulin is a binding protein of inhibin and activin.
Endocrinology 1993;132(5):2038-50.
1993: D G Parkes; G Y Yamamoto; J M Vaughan; Wylie W Vale
Characterization and regulation of corticotropin-releasing factor in the human hepatoma NPLC-KC cell line.
Neuroendocrinology 1993;57(4):663-9.
1993: D P Behan; E Potter; K A Lewis; N A Jenkins; N Copeland; Philip J Lowry; Wylie W Vale
Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP)
Genomics 1993;16(1):63-8.
1993: K Tsuchida; K A Lewis; L S Mathews; Wylie W Vale
Molecular characterization of rat transforming growth factor-beta type II receptor.
Biochemical and biophysical research communications 1993;191(3):790-5.
1993: Marilyn H Perrin; Louise M Bilezikjian; C Hoeger; Cynthia J Donaldson; Jean Rivier; Y Haas; Wylie W Vale
Molecular and functional characterization of GnRH receptors cloned from rat pituitary and a mouse pituitary tumor cell line.
Biochemical and biophysical research communications 1993;191(3):1139-44.
1993: Mary P Stenzel-Poore; Wylie W Vale; Catherine Rivier
Relationship between antigen-induced immune stimulation and activation of the hypothalamic-pituitary-adrenal axis in the rat.
Endocrinology 1993;132(3):1313-8.
1993: L S Mathews; Wylie W Vale
Molecular and functional characterization of activin receptors.
Receptor 1993;3(3):173-81.
1992: R Scott Struthers; D Gaddy-Kurten; Wylie W Vale
Activin inhibits binding of transcription factor Pit-1 to the growth hormone promoter.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(23):11451-5.
1992: Mary P Stenzel-Poore; KA Heldwein; Peter Stenzel; Soon Lee; Wylie W Vale
Characterization of the genomic corticotropin-releasing factor (CRF) gene from Xenopus laevis: two members of the CRF family exist in amphibians.
Molecular endocrinology (Baltimore, Md.) 1992;6(10):1716-24.
1992: E Potter; D P Behan; EA Linton; Philip J Lowry; Paul E Sawchenko; Wylie W Vale
The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(9):4192-6.
1992: Cynthia J Donaldson; L S Mathews; Wylie W Vale
Molecular cloning and binding properties of the human type II activin receptor.
Biochemical and biophysical research communications 1992;184(1):310-6.
1992: L S Mathews; Wylie W Vale; C R Kintner
Cloning of a second type of activin receptor and functional characterization in Xenopus embryos.
Science (New York, N.Y.) 1992;255(5052):1702-5.
1991: L S Mathews; Wylie W Vale
Expression cloning of an activin receptor, a predicted transmembrane serine kinase.
Cell 1991;65(6):973-82.
1991: R Scott Struthers; Wylie W Vale; C Arias; Paul E Sawchenko; Marc Montminy
Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant.
Nature 1991;350(6319):622-4.
1991: E Potter; D P Behan; Wolfgang H Fischer; EA Linton; Philip J Lowry; Wylie W Vale
Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins.
Nature 1991;349(6308):423-6.
1990: M Baes; Wylie W Vale
Characterization of the glucose-dependent release of growth hormone-releasing factor and somatostatin from superfused rat hypothalami.
Neuroendocrinology 1990;51(2):202-7.
1989: G A Gonzalez; K K Yamamoto; Wolfgang H Fischer; D Karr; P Menzel; W Biggs; Wylie W Vale; Marc Montminy
A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence.
Nature 1989;337(6209):749-52.
1989: M Baes; Wylie W Vale
Growth hormone-releasing factor secretion from fetal hypothalamic cell cultures is modulated by forskolin, phorbol esters, and muscimol.
Endocrinology 1989;124(1):104-10.
1988: E P Widmaier; Paul M Plotsky; S W Sutton; Wylie W Vale
Regulation of corticotropin-releasing factor secretion in vitro by glucose.
The American journal of physiology 1988;255(3 Pt 1):E287-92.
1987: Louise M Bilezikjian; J R Woodgett; Tony Hunter; Wylie W Vale
Phorbol ester-induced down-regulation of protein kinase C abolishes vasopressin-mediated responses in rat anterior pituitary cells.
Molecular endocrinology (Baltimore, Md.) 1987;1(8):555-60.
1987: Louise M Bilezikjian; A L Blount; Wylie W Vale
The cellular actions of vasopressin on corticotrophs of the anterior pituitary: resistance to glucocorticoid action.
Molecular endocrinology (Baltimore, Md.) 1987;1(7):451-8.
1987: Louise M Bilezikjian; J Erlichman; Norman Fleischer; Wylie W Vale
Differential activation of type I and type II 3',5'-cyclic adenosine monophosphate-dependent protein kinases by growth hormone-releasing factor.
Molecular endocrinology (Baltimore, Md.) 1987;1(2):137-46.
1987: Louise M Bilezikjian; Wylie W Vale
Regulation of ACTH secretion from corticotrophs: the interaction of vasopressin and CRF.
Annals of the New York Academy of Sciences 1987;512():85-96.
1986: T O Bruhn; S W Sutton; Paul M Plotsky; Wylie W Vale
Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat.
Endocrinology 1986;119(4):1558-63.
1986: Marilyn H Perrin; Y Haas; Jean E Rivier; Wylie W Vale
Corticotropin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides.
Endocrinology 1986;118(3):1171-9.
1983: Marilyn H Perrin; Y Haas; Jean E Rivier; Wylie W Vale
Solubilization of the gonadotropin-releasing hormone receptor from bovine pituitary plasma membranes.
Endocrinology 1983;112(4):1538-40.
1983: Marilyn H Perrin; Y Haas; Jean E Rivier; Wylie W Vale
Gonadotropin-releasing hormone binding to rat anterior pituitary membrane homogenates. Comparison of antagonists and agonists using radiolabeled antagonist and agonist.
Molecular pharmacology 1983;23(1):44-51.
1980: Marilyn H Perrin; J M Vaughan; Jean E Rivier; Wylie W Vale
High affinity GNRH binding to testicular membrane homogenates.
Life sciences 1980;26(26):2251-5.